INDV Stock: Price, Earnings History and SEC Filings
Indivior Pharmaceuticals, Inc. (INDV) last traded at $35.37, up 0.34% on the latest session and down 1.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $1.32 against an analyst estimate of $0.93, a beat of 41.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
INDV earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 29, 2026 | $1.32 | $0.93 | +41.94% |
| Jun 2026 | Aug 3, 2026 | $1.15 | $0.97 | +18.56% |
| Mar 2026 | Apr 30, 2026 | $0.96 | $0.64 | +50.00% |
| Dec 2025 | Feb 26, 2026 | $0.82 | $0.65 | +26.15% |
INDV beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How INDV reacts to earnings
Across its last 7 earnings releases, INDV moved 8.8% on average the next session, in either direction. It rose after 6 of 7 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-29 | Before open | +1.38% |
| 2026-08-03 | Before open | -6.60% |
| 2026-04-30 | Before open | +7.70% |
| 2026-02-26 | Before open | +0.24% |
| 2025-10-30 | Before open | +15.41% |
| 2025-07-31 | Before open | +16.09% |
| 2025-04-23 | After close | +13.86% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
INDV financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.2B | $210M | -$93M | 16.9% | $1.64 |
| 2024 | $1.2B | $7M | $7M | 0.6% | $0.05 |
| 2023 | $1.1B | -$126M | -$308M | -11.5% | $-0.92 |
| 2022 | $901M | -$44M | -$9M | -4.9% | $-0.32 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for INDV
- 10-Q · Oct 29, 2026
- 8-K · Oct 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 15, 2026Shareholder vote
- 8-K · Oct 6, 2026Other events
- 8-K · Sep 17, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 15, 2026Agreement terminated, Financial statements and exhibits
- 424B3 · Sep 11, 2026
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 3, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
INDV insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
INDV news
- Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround NarrativeOct 30, 2026 · finance.yahoo.com
- Indivior PlcOct 30, 2026 · 247wallst.com
- Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third QuarterOct 30, 2026 · finance.yahoo.com
- Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Indivior Reports Third Quarter 2026 Financial ResultsOct 29, 2026 · finance.yahoo.com
- Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600Oct 28, 2026 · finance.yahoo.com
- MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600Oct 22, 2026 · finance.yahoo.com
- Indivior to Report Third Quarter 2026 Financial ResultsOct 19, 2026 · finance.yahoo.com
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. (INDV) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.